|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
decreases activity |
ISO |
iloperidone results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
affects abundance multiple interactions increases export increases transport affects response to substance decreases activity |
ISO EXP |
ABCB1 gene polymorphism affects the abundance of Paliperidone Palmitate; ABCB1 protein affects the abundance of Paliperidone Palmitate Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Paliperidone Palmitate] ABCB1A protein results in increased transport of Paliperidone Palmitate ABCB1A protein affects the susceptibility to Paliperidone Palmitate Paliperidone Palmitate results in decreased activity of ABCB1 protein Paliperidone Palmitate inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin] ABCB1 protein results in increased transport of Paliperidone Palmitate |
CTD |
PMID:15502009 PMID:16118767 PMID:16810505 PMID:16936711 PMID:17541883 PMID:22691713 More...
|
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects response to substance |
EXP |
ABCB1B protein affects the susceptibility to Paliperidone Palmitate |
CTD |
PMID:15502009 |
|
NCBI chr 5:8,848,147...8,916,314
Ensembl chr 5:8,848,147...8,916,315
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
decreases activity |
ISO |
Paliperidone Palmitate results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
ISO |
Paliperidone Palmitate inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Bdnf |
brain derived neurotrophic factor |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of BDNF mRNA |
CTD |
PMID:21220416 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of CXCL8 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
affects abundance |
ISO |
CYP2D6 gene polymorphism affects the abundance of Paliperidone Palmitate; CYP2D6 protein affects the abundance of Paliperidone Palmitate |
CTD |
PMID:10639689 PMID:15089809 PMID:17541883 |
|
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions affects binding |
ISO |
Paliperidone Palmitate binds to and results in decreased activity of DRD2 protein Paliperidone Palmitate binds to DRD2 protein |
CTD |
PMID:19713555 PMID:22437487 |
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression multiple interactions |
ISO |
Paliperidone Palmitate results in increased expression of FADS2 mRNA [Paliperidone Palmitate results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated |
CTD |
PMID:21458237 |
|
NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110
|
|
G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A |
affects binding multiple interactions |
ISO |
Paliperidone Palmitate binds to HTR2A protein Paliperidone Palmitate binds to and results in decreased activity of HTR2A protein |
CTD |
PMID:7520908 PMID:19713555 PMID:22437487 |
|
NCBI chr14:74,878,314...74,944,299
Ensembl chr14:74,878,280...74,946,934
|
|
G |
Htr7 |
5-hydroxytryptamine (serotonin) receptor 7 |
multiple interactions |
ISO |
[Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein |
CTD |
PMID:18996971 PMID:19509219 PMID:20827463 |
|
NCBI chr19:35,935,815...36,035,533
Ensembl chr19:35,936,134...36,034,907
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity |
ISO |
Paliperidone Palmitate results in decreased activity of KCNH2 protein |
CTD |
PMID:21394035 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of PRL protein |
CTD |
PMID:17460786 PMID:19825908 |
|
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
|
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
increases response to substance affects abundance affects response to substance increases transport multiple interactions decreases activity increases export |
ISO EXP |
ABCB1 protein results in increased susceptibility to Risperidone ABCB1 gene polymorphism affects the abundance of Risperidone; ABCB1 protein affects the abundance of Risperidone ABCB1 gene polymorphism affects the susceptibility to Risperidone; ABCB1 protein affects the susceptibility to Risperidone ABCB1 protein results in increased transport of Risperidone Risperidone inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin] Risperidone results in decreased activity of ABCB1 protein ABCB1A protein results in increased transport of Risperidone ABCB1A protein results in increased export of Risperidone ABCB1A protein affects the susceptibility to Risperidone Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Risperidone] |
CTD |
PMID:15502009 PMID:16118767 PMID:16810505 PMID:16936711 PMID:17054409 PMID:17541883 PMID:18708991 PMID:19997080 PMID:20563569 PMID:21449914 PMID:22623266 PMID:22691713 More...
|
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects response to substance |
EXP |
ABCB1B protein affects the susceptibility to Risperidone |
CTD |
PMID:15502009 |
|
NCBI chr 5:8,848,147...8,916,314
Ensembl chr 5:8,848,147...8,916,315
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
ISO |
Risperidone inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone]; Risperidone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:18834354 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Bdnf |
brain derived neurotrophic factor |
decreases expression multiple interactions |
ISO |
Risperidone results in decreased expression of BDNF mRNA Risperidone inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA] BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] |
CTD |
PMID:12393228 PMID:17442543 PMID:19997080 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
ISO |
Risperidone results in increased expression of CALM2 mRNA |
CTD |
PMID:19289156 |
|
NCBI chr17:87,740,829...87,754,363
Ensembl chr17:87,740,840...87,754,363
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
decreases expression |
ISO |
Risperidone results in decreased expression of CAMK2A protein |
CTD |
PMID:19289156 |
|
NCBI chr18:61,058,704...61,121,224
Ensembl chr18:61,058,690...61,121,224
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression |
ISO |
Risperidone results in decreased expression of CAMK4 protein |
CTD |
PMID:19289156 |
|
NCBI chr18:33,067,995...33,328,820
Ensembl chr18:33,067,984...33,324,281
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1, alpha |
decreases expression |
ISO |
Risperidone results in decreased expression of CAMKK1 protein |
CTD |
PMID:19289156 |
|
NCBI chr11:72,906,869...72,932,899
Ensembl chr11:72,909,834...72,932,899
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2, beta |
decreases expression |
ISO |
Risperidone results in decreased expression of CAMKK2 protein |
CTD |
PMID:19289156 |
|
NCBI chr 5:122,856,064...122,918,295
Ensembl chr 5:122,869,233...122,917,472
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP3 protein] |
CTD |
PMID:22700542 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Risperidone results in increased expression of CEBPA mRNA; Risperidone results in increased expression of CEBPA protein |
CTD |
PMID:20564506 |
|
NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
affects response to substance |
EXP |
CHRM4 affects the susceptibility to Risperidone |
CTD |
PMID:21269601 |
|
NCBI chr 2:91,752,531...91,760,180
Ensembl chr 2:91,757,594...91,759,033
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
Risperidone results in increased expression of COMT mRNA |
CTD |
PMID:15964593 |
|
NCBI chr16:18,225,632...18,247,006
Ensembl chr16:18,225,636...18,245,602
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Risperidone results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO |
DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein] |
CTD |
PMID:16144542 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
affects response to substance decreases hydroxylation decreases metabolic processing affects abundance multiple interactions affects metabolic processing increases metabolic processing increases response to substance |
ISO |
CYP2D6 gene polymorphism affects the susceptibility to Risperidone; CYP2D6 protein polymorphism affects the susceptibility to Risperidone CYP2D6 gene polymorphism results in decreased hydroxylation of Risperidone CYP2D6 gene polymorphism results in decreased metabolism of Risperidone CYP2D6 gene polymorphism affects the abundance of Risperidone; CYP2D6 protein affects the abundance of Risperidone CYP2D6 gene polymorphism affects the metabolism of and affects the abundance of Risperidone; CYP2D6 protein affects the metabolism of and affects the abundance of Risperidone CYP2D6 gene polymorphism affects the metabolism of Risperidone; CYP2D6 protein affects the metabolism of Risperidone CYP2D6 protein results in increased metabolism of Risperidone CYP2D6 protein results in increased susceptibility to Risperidone |
CTD |
PMID:10639689 PMID:15089809 PMID:15260906 PMID:15565299 PMID:15669884 PMID:16044105 PMID:17224713 PMID:17541883 PMID:18708991 PMID:19387994 PMID:20332423 PMID:20563569 PMID:21449914 PMID:22623266 PMID:22745940 PMID:23609392 More...
|
|
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
affects abundance increases metabolic processing |
ISO |
CYP3A5 gene polymorphism affects the abundance of Risperidone; CYP3A5 protein affects the abundance of Risperidone CYP3A5 protein results in increased metabolism of Risperidone |
CTD |
PMID:18708991 PMID:20332423 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions affects response to substance increases response to substance affects binding |
ISO |
Risperidone binds to and results in decreased activity of DRD2 protein DRD2 gene polymorphism affects the susceptibility to Risperidone DRD2 gene polymorphism results in increased susceptibility to Risperidone; DRD2 gene SNP results in increased susceptibility to Risperidone; DRD2 protein results in increased susceptibility to Risperidone Risperidone binds to DRD2 protein [Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein]; Risperidone binds to and results in decreased activity of DRD2 protein; Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein]; Risperidone promotes the reaction [Dopamine binds to DRD2 protein] |
CTD |
PMID:1380082 PMID:7520908 PMID:8804920 PMID:10831489 PMID:12191584 PMID:15710053 PMID:15716360 PMID:16033416 PMID:16144542 PMID:16513859 PMID:18058087 PMID:19339912 PMID:19640686 PMID:19910723 PMID:20361897 PMID:20375926 PMID:21869689 PMID:22437487 PMID:22967779 More...
|
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Drd3 |
dopamine receptor D3 |
increases response to substance |
ISO |
DRD3 gene SNP results in increased susceptibility to Risperidone; DRD3 protein results in increased susceptibility to Risperidone |
CTD |
PMID:19506579 PMID:19997080 |
|
NCBI chr16:43,574,285...43,646,353
Ensembl chr16:43,574,389...43,643,295
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
multiple interactions increases expression |
ISO |
DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein] |
CTD |
PMID:16144542 |
|
NCBI chr16:20,335,694...20,352,763
Ensembl chr16:20,335,732...20,352,760
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
ISO |
Risperidone results in decreased expression of EGR1 protein |
CTD |
PMID:17028028 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Egr2 |
early growth response 2 |
decreases expression multiple interactions |
ISO EXP |
Risperidone results in decreased expression of EGR2 protein Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR2 protein]] |
CTD |
PMID:17028028 PMID:32980479 |
|
NCBI chr10:67,370,334...67,383,354
Ensembl chr10:67,371,305...67,378,018
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
increases phosphorylation |
ISO |
Risperidone results in increased phosphorylation of ERBB2 protein |
CTD |
PMID:26961615 |
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
Risperidone results in increased expression of and results in increased phosphorylation of ERBB4 protein |
CTD |
PMID:26961615 |
|
NCBI chr 1:68,071,063...69,147,756
Ensembl chr 1:68,071,345...69,147,218
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression multiple interactions |
ISO |
Risperidone results in increased expression of FADS2 mRNA [Risperidone results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated |
CTD |
PMID:21458237 |
|
NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions increases expression |
ISO EXP |
Risperidone promotes the reaction [Rotenone results in increased expression of FOS mRNA] Risperidone results in increased expression of FOS mRNA Dronabinol inhibits the reaction [Risperidone results in increased expression of FOS protein]; Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of FOS protein]] |
CTD |
PMID:11516571 PMID:17442543 PMID:28272498 PMID:32980479 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Fshb |
follicle stimulating hormone beta |
affects expression |
ISO |
Risperidone affects the expression of FSHB protein |
CTD |
PMID:18838228 |
|
NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GGT1 protein]; coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GGT1 protein]; Risperidone results in increased expression of and results in increased secretion of GGT1 protein |
CTD |
PMID:27387968 |
|
NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1, soluble |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GOT1 protein]; coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GOT1 protein]; Risperidone results in increased expression of and results in increased secretion of GOT1 protein |
CTD |
PMID:27387968 |
|
NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GPT protein]; coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GPT protein]; Risperidone results in increased expression of and results in increased secretion of GPT protein |
CTD |
PMID:27387968 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
increases expression multiple interactions |
ISO |
Risperidone results in increased expression of GSK3A protein DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein] |
CTD |
PMID:16144542 |
|
NCBI chr 7:24,927,683...24,937,276
Ensembl chr 7:24,927,683...24,937,276
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression |
ISO |
DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein] |
CTD |
PMID:16144542 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
increases expression |
ISO |
Risperidone results in increased expression of HMGCR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Homer1 |
homer scaffolding protein 1 |
increases expression |
ISO |
Risperidone results in increased expression of HOMER1 mRNA |
CTD |
PMID:20147574 |
|
NCBI chr13:93,440,265...93,549,471
Ensembl chr13:93,436,143...93,541,637
|
|
G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A |
increases response to substance multiple interactions |
ISO |
HTR1A protein results in increased susceptibility to Risperidone N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [HTR1A protein results in increased susceptibility to Risperidone] |
CTD |
PMID:17530476 |
|
NCBI chr13:105,580,040...105,584,630
Ensembl chr13:105,580,147...105,584,630
|
|
G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A |
increases response to substance affects response to substance multiple interactions affects binding |
ISO |
HTR2A gene SNP results in increased susceptibility to Risperidone; HTR2A protein results in increased susceptibility to Risperidone HTR2A protein affects the susceptibility to Risperidone HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; Risperidone binds to and results in decreased activity of HTR2A protein Risperidone binds to and results in decreased activity of HTR2A protein; Risperidone inhibits the reaction [Ketanserin binds to HTR2A protein] Risperidone binds to HTR2A protein |
CTD |
PMID:7520908 PMID:11927170 PMID:12191584 PMID:16314884 PMID:16948927 PMID:19997080 PMID:22437487 More...
|
|
NCBI chr14:74,878,314...74,944,299
Ensembl chr14:74,878,280...74,946,934
|
|
G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C |
affects response to substance increases response to substance multiple interactions |
ISO |
HTR2C gene polymorphism affects the susceptibility to Risperidone; HTR2C protein affects the susceptibility to Risperidone HTR2C protein results in increased susceptibility to Risperidone HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] |
CTD |
PMID:19142101 PMID:19997080 |
|
NCBI chr X:145,745,509...145,980,273
Ensembl chr X:145,745,509...145,980,273
|
|
G |
Htr6 |
5-hydroxytryptamine (serotonin) receptor 6 |
multiple interactions |
ISO |
HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] |
CTD |
PMID:19997080 |
|
NCBI chr 4:138,787,017...138,802,881
Ensembl chr 4:138,788,419...138,802,881
|
|
G |
Htr7 |
5-hydroxytryptamine (serotonin) receptor 7 |
multiple interactions |
ISO |
2-((2-(dimethylamino)ethyl)thio)-3-phenylquinoline inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Clozapine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Cyproheptadine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; mesulergine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Mianserin inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Risperidone binds to and results in decreased activity of HTR7 protein; SB 269970 inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein] |
CTD |
PMID:18996971 PMID:19509219 PMID:20827463 |
|
NCBI chr19:35,935,815...36,035,533
Ensembl chr19:35,936,134...36,034,907
|
|
G |
Inha |
inhibin alpha |
multiple interactions |
ISO |
Risperidone results in increased expression of [INHA protein binds to INHBB protein] |
CTD |
PMID:18838228 |
|
NCBI chr 1:75,483,872...75,487,010
Ensembl chr 1:75,483,721...75,487,010
|
|
G |
Inhbb |
inhibin beta-B |
multiple interactions |
ISO |
Risperidone results in increased expression of [INHA protein binds to INHBB protein] |
CTD |
PMID:18838228 |
|
NCBI chr 1:119,343,193...119,349,978
Ensembl chr 1:119,343,195...119,349,978
|
|
G |
Ins2 |
insulin II |
increases expression |
ISO |
Risperidone results in increased expression of INS protein |
CTD |
PMID:11927762 PMID:16601995 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
multiple interactions |
ISO |
Risperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:21158687 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Maoa |
monoamine oxidase A |
affects response to substance increases response to substance |
ISO |
MAOA gene polymorphism affects the susceptibility to Risperidone MAOA protein results in increased susceptibility to Risperidone |
CTD |
PMID:22544010 |
|
NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057
|
|
G |
Maob |
monoamine oxidase B |
increases expression |
ISO |
Risperidone results in increased expression of MAOB mRNA |
CTD |
PMID:15964593 |
|
NCBI chr X:16,575,520...16,683,605
Ensembl chr X:16,575,521...16,683,605
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
Risperidone results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742
|
|
G |
Ngfr |
nerve growth factor receptor (TNFR superfamily, member 16) |
decreases expression |
ISO |
Risperidone results in decreased expression of NGFR mRNA |
CTD |
PMID:12111809 PMID:16513140 |
|
NCBI chr11:95,459,644...95,478,524
Ensembl chr11:95,459,644...95,478,561
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:21402137 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
ISO |
Risperidone results in increased expression of NRG1 protein |
CTD |
PMID:26961615 |
|
NCBI chr 8:32,299,493...33,381,858
Ensembl chr 8:32,304,579...33,374,825 Ensembl chr 8:32,304,579...33,374,825
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
increases expression multiple interactions |
EXP |
Risperidone results in increased expression of PPARG mRNA; Risperidone results in increased expression of PPARG protein Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] |
CTD |
PMID:20564506 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppp3ca |
protein phosphatase 3, catalytic subunit, alpha isoform |
multiple interactions decreases expression |
ISO |
[Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein Risperidone results in decreased expression of PPP3CA mRNA; Risperidone results in decreased expression of PPP3CA protein |
CTD |
PMID:16033416 |
|
NCBI chr 3:136,375,778...136,643,488
Ensembl chr 3:136,375,885...136,643,488
|
|
G |
Prl |
prolactin |
multiple interactions increases secretion increases expression |
ISO |
[Risperidone co-treated with Clozapine] results in increased expression of PRL protein; Aripiprazole inhibits the reaction [Risperidone results in increased secretion of PRL protein]; BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] Risperidone inhibits the reaction [Dopamine results in decreased secretion of PRL protein] |
CTD |
PMID:1380082 PMID:9696519 PMID:9989566 PMID:10084644 PMID:11048906 PMID:11155212 PMID:11561931 PMID:11927762 PMID:12902212 PMID:12974991 PMID:15206663 PMID:15286066 PMID:15289996 PMID:15669890 PMID:15960571 PMID:16379509 PMID:16730335 PMID:17224713 PMID:18063941 PMID:18080171 PMID:18466271 PMID:18562423 PMID:18759643 PMID:18838228 PMID:19653986 PMID:19825908 PMID:19906340 PMID:19997080 PMID:20373475 PMID:20661022 PMID:20814333 More...
|
|
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
ISO |
Risperidone results in increased expression of RGS2 mRNA |
CTD |
PMID:11516571 |
|
NCBI chr 1:143,875,076...143,879,887
Ensembl chr 1:143,875,076...143,879,899
|
|
G |
S100b |
S100 protein, beta polypeptide, neural |
increases secretion |
ISO |
Risperidone results in increased secretion of S100B protein |
CTD |
PMID:18421423 |
|
NCBI chr10:76,089,670...76,097,153
Ensembl chr10:76,089,687...76,096,993
|
|
G |
Slc17a6 |
solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6 |
increases expression |
EXP |
Risperidone results in increased expression of SLC17A6 mRNA; Risperidone results in increased expression of SLC17A6 protein |
CTD |
PMID:18155072 |
|
NCBI chr 7:51,271,578...51,320,874
Ensembl chr 7:51,271,754...51,320,867
|
|
G |
Snap25 |
synaptosomal-associated protein 25 |
affects response to substance |
ISO |
SNAP25 gene SNP affects the susceptibility to Risperidone |
CTD |
PMID:15823421 |
|
NCBI chr 2:136,555,359...136,624,348
Ensembl chr 2:136,555,373...136,624,348
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions increases expression |
ISO |
Risperidone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA]; Risperidone inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein] Risperidone results in increased expression of SOD1 mRNA |
CTD |
PMID:12111809 PMID:12752374 PMID:16564057 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Risperidone results in increased expression of SREBF1 mRNA; Risperidone results in increased expression of SREBF1 protein |
CTD |
PMID:20564506 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Risperidone inhibits the reaction [Rotenone results in decreased expression of STAT3 mRNA] |
CTD |
PMID:17442543 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
ISO |
Risperidone results in increased expression of TH protein |
CTD |
PMID:17028028 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions |
ISO |
zonisamide binds to and results in decreased activity of CA1 protein |
CTD |
PMID:17826101 |
|
NCBI chr 3:14,831,274...14,873,425
Ensembl chr 3:14,831,276...14,873,428
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
zonisamide binds to and results in decreased activity of CA2 protein |
CTD |
PMID:17826101 |
|
NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
zonisamide binds to and results in decreased activity of CA3 protein |
CTD |
PMID:17826101 |
|
NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO |
DRD1 protein promotes the reaction [zonisamide affects the secretion of Dopamine]; DRD1 protein promotes the reaction [zonisamide affects the secretion of gamma-Aminobutyric Acid] |
CTD |
PMID:19482038 |
|
NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
ISO |
zonisamide inhibits the reaction [Tacrine results in increased expression of FOS protein] |
CTD |
PMID:18693129 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
zonisamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein] |
CTD |
PMID:19199078 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Ifng |
interferon gamma |
decreases expression |
EXP |
zonisamide results in decreased expression of IFNG protein |
CTD |
PMID:10982153 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Maob |
monoamine oxidase B |
multiple interactions decreases activity |
EXP |
zonisamide inhibits the reaction [[MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased chemical synthesis of 1-Methyl-4-phenylpyridinium]; zonisamide inhibits the reaction [Selegiline binds to MAOB protein] zonisamide results in decreased activity of MAOB protein |
CTD |
PMID:19948168 |
|
NCBI chr X:16,575,520...16,683,605
Ensembl chr X:16,575,521...16,683,605
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
increases expression |
ISO |
zonisamide results in increased expression of NOS2 mRNA |
CTD |
PMID:12429386 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Slc1a1 |
solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 |
increases expression |
ISO |
zonisamide results in increased expression of SLC1A1 protein |
CTD |
PMID:12941455 |
|
NCBI chr19:28,812,535...28,891,360
Ensembl chr19:28,812,449...28,891,360
|
|
G |
Th |
tyrosine hydroxylase |
increases expression multiple interactions |
ISO EXP |
zonisamide results in increased expression of TH mRNA; zonisamide results in increased expression of TH protein [zonisamide co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] affects the activity of TH protein; zonisamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] |
CTD |
PMID:19199078 PMID:19948168 PMID:20196486 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|